Alstrom syndrome natural history, complications and prognosis: Difference between revisions
| Line 11: | Line 11: | ||
|-style="background:silver; color:black" align="center" | |-style="background:silver; color:black" align="center" | ||
| '''Manifestation''' || '''Range of Age Onset''' || '''Incidence''' | | '''Manifestation''' || '''Range of Age Onset''' || '''Incidence''' | ||
|-style="background:white; color:black" | |-style="background:white; color:black" align="center" | ||
| Cone-rod dystrophy || Birth - 15 mos || 100% | | Cone-rod dystrophy || Birth - 15 mos || 100% | ||
|-style="background:white; color:black" | |-style="background:white; color:black" align="center" | ||
| Obesity || Birth - 5 years || 98% | | Obesity || Birth - 5 years || 98% | ||
|-style="background:white; color:black" | |-style="background:white; color:black" align="center" | ||
| Developmental delay || Birth-adolescence || 25%-30% | | Developmental delay || Birth-adolescence || 25%-30% | ||
|-style="background:white; color:black" | |-style="background:white; color:black" align="center" | ||
| Dilated cardiomyopathy || 2 wks - 4 mos || 42% | | Dilated cardiomyopathy || 2 wks - 4 mos || 42% | ||
|-style="background:white; color:black" | |-style="background:white; color:black" align="center" | ||
| Progressive sensorineural hearing loss || 2-25 yrs || 88% | | Progressive sensorineural hearing loss || 2-25 yrs || 88% | ||
|-style="background:white; color:black" | |-style="background:white; color:black" align="center" | ||
| Restrictive cardiomyopathy || Juvenile - late 30s || 18% | | Restrictive cardiomyopathy || Juvenile - late 30s || 18% | ||
|-style="background:white; color:black" | |-style="background:white; color:black" align="center" | ||
| Insulin resistance / type 2 diabetes mellitus || 4-30 yrs / 8-40 yrs || 92% / 68% | | Insulin resistance / type 2 diabetes mellitus || 4-30 yrs / 8-40 yrs || 92% / 68% | ||
|-style="background:white; color:black" | |-style="background:white; color:black" align="center" | ||
| Short stature || Puberty - adult || 98% | | Short stature || Puberty - adult || 98% | ||
|-style="background:white; color:black" | |-style="background:white; color:black" align="center" | ||
| Hepatic disease || 8-30 yrs || 23%-92% | | Hepatic disease || 8-30 yrs || 23%-92% | ||
|-style="background:white; color:black" | |-style="background:white; color:black" align="center" | ||
| Hypogonadotropic hypogonadism || 10+ yrs || 78% of males | | Hypogonadotropic hypogonadism || 10+ yrs || 78% of males | ||
|-style="background:white; color:black" | |-style="background:white; color:black" align="center" | ||
| Urologic disease || Adolescence - adult || 48% | | Urologic disease || Adolescence - adult || 48% | ||
|-style="background:white; color:black" | |-style="background:white; color:black" align="center" | ||
| Renal disease || Adolescence - adult || Variably progressive with age | | Renal disease || Adolescence - adult || Variably progressive with age | ||
|} | |} | ||
Revision as of 19:23, 25 February 2013
|
Alstrom syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Alstrom syndrome natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Alstrom syndrome natural history, complications and prognosis |
|
FDA on Alstrom syndrome natural history, complications and prognosis |
|
CDC on Alstrom syndrome natural history, complications and prognosis |
|
Alstrom syndrome natural history, complications and prognosis in the news |
|
Blogs on Alstrom syndrome natural history, complications and prognosis |
|
Risk calculators and risk factors for Alstrom syndrome natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]; Raviteja Guddeti, M.B.B.S. [3]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Natural History
A wide range of clinical variability is observed among individuals with Alström syndrome, including among siblings. The first clinical presentation of Alström syndrome is usually nystagmus caused by cone-rod dystrophy and resulting in childhood blindness. Disease characteristics that are later in onset include truncal obesity that manifests during the first year of life, progressive sensorineural hearing loss, infantile-onset dilated cardiomyopathy or later-onset restrictive cardiomyopathy, insulin-resistant type 2 diabetes mellitus, and hepatic, pulmonary, and renal dysfunction.
| Manifestation | Range of Age Onset | Incidence |
| Cone-rod dystrophy | Birth - 15 mos | 100% |
| Obesity | Birth - 5 years | 98% |
| Developmental delay | Birth-adolescence | 25%-30% |
| Dilated cardiomyopathy | 2 wks - 4 mos | 42% |
| Progressive sensorineural hearing loss | 2-25 yrs | 88% |
| Restrictive cardiomyopathy | Juvenile - late 30s | 18% |
| Insulin resistance / type 2 diabetes mellitus | 4-30 yrs / 8-40 yrs | 92% / 68% |
| Short stature | Puberty - adult | 98% |
| Hepatic disease | 8-30 yrs | 23%-92% |
| Hypogonadotropic hypogonadism | 10+ yrs | 78% of males |
| Urologic disease | Adolescence - adult | 48% |
| Renal disease | Adolescence - adult | Variably progressive with age |
Complications
- Blindness
- Hearing loss
- Congestive heart failure
- Cirrhosis
- Pancreatitis
- ESRD
- Hypothyroidism
- Pulmonary fibrosis
- Portal hypertension
- Type 2 diabetes mellitus
- Stunted growth